Johnson & Johnson Archives

The Insulin Pump That Could Spark a Bidding War: Modular Medical’s Pivot Targets Millions Still on Manual Injections -( $ABT $JNJ $MDT $MMED $MODD $PODD $TNDM )

by John F. Heerdink, Jr. May 22, 2026 920Views 0Likes

Modular Medical (MODD) has cleared a crucial regulatory hurdle that positions its Pivot insulin patch pump as a potential game-changer in the $7 billion diabetes technology market, with FDA 510(k) clearance paving the way for commercial shipments by the end of Q2…

From Viral Load to Order Book: What the Congo Ebola Outbreak Could Mean for Vaccine Names -( $MRK $JNJ $GOVX )

by John F. Heerdink, Jr. May 18, 2026 389Views 0Likes

A new Ebola outbreak in Congo is once again testing global health systems, but it is also spotlighting a small group of vaccine developers who have spent the quiet years preparing for noisy ones like this. As health agencies scramble on the…

FDA Musical Chairs: What the Latest Leadership Shuffle Means for Biotech Investors -( $IBB $XBI )

by John F. Heerdink, Jr. May 16, 2026 430Views 0Likes

The FDA’s latest reshuffle of its top drug and biologics leaders lands biotech in yet another plot twist—but this one may read more like a quirky chapter break than a full-blown cliffhanger for investors. FDA’s New Cast at the Top The Food…

Not Just Chips and Giggles: Pairing High‑Flying Tech With Serious Healthcare Winners -( $AI $AMD $CAH $CVS $EPRX $MODD $JNJ $NVDA $PODD $TNDM )

by John F. Heerdink, Jr. April 24, 2026 594Views 0Likes

Investors are quietly building a new playbook: keep riding the AI rocket, but pair it with old‑economy resilience and under‑the‑radar healthcare innovators that actually move the needle in patients’ lives. When Tech Flies Too Close to the Sun Wall Street’s love affair…

Is Nanobiotix Building a Toll Road for Genetic Drugs? Early Preclinical Data Says “Maybe” -( $NBTX $JNJ $IBB $XBI )

by John F. Heerdink, Jr. April 23, 2026 488Views 0Likes

Nanobiotix’s (NBTX) latest preclinical data suggest that its Nanoprimer technology may do for lipid nanoparticle (LNP) DNA immunotherapy what noise-cancelling headphones did for air travel: make a powerful experience markedly more tolerable. For investors watching the crossroad of oncology and genetic medicines,…

Inside Biopharma’s 2025 Deal Wave: Record Licensing, Big Pharma M&A and a Frozen IPO Market -( $JPM $IBB $XBI $LLY $MRK $NVS $PFE )

by John F. Heerdink, Jr. January 21, 2026 460Views 0Likes

Biopharma spent 2025 behaving like a sector that has finally read the fine print on the cost of capital—and decided to let someone else pick up the bar tab. Licensing and M&A stepped into the role IPOs used to play, and did…

The Year of the Bispecific: Biotech’s Double-Edged Breakout -( $ARKG $IBB $XBI $RHBBY $AMGN $JNJ )

by Vista Partners LLC December 10, 2025 446Views 0Likes

If 2024 crowned weight-loss drugs the belle of the healthcare ball, 2025 belongs to the bispecific antibody. What began as a niche in immuno-oncology has evolved into biotech’s most competitive—and potentially lucrative—battleground, drawing fresh capital, dealmaking, and analyst optimism that borders on…

S&P 500, Nasdaq Rally as Rate‑Cut Bets Lift -Nov. 24, 2025 -( $AAPL $AVGO $GOOG $INTC $LLY $META $NOK $OPEN $SOAR $TSLA Rise!)

by Vista Partners LLC November 24, 2025 3669Views 0Likes

Wall Street shook off its November sulk on Monday, with the major benchmarks staging a rate-cut–hope rally that looked suspiciously like early Christmas cheer delivered by central bankers rather than Santa. The S&P 500 climbed about 1.55% to roughly 6,705.12, the Dow…

From Lilly’s Defensiveness to Tesla’s Turbulence: Winners and Laggards in a Volatile Week for Wall Street -( $DV $EXAS $INTG $JNJ $LLY $MCD $SOAR $VIX Rise!)

by Vista Partners LLC November 21, 2025 3414Views 0Likes

Large caps took a hit this week with the Dow 30 ending at 46,245.41, -1.9% & the S&P 500 closed at 6,602.99 equally off 1.9%. The high-beta tech kept the Nasdaq on the defensive for most of the week and fell 2.7%…

Wall Street Sputters on AI Jitters: Nasdaq Slide, Walmart Exceeds, & Exact Sciences’ $23B Buyout Lead Market Moves – Nov. 20,2025 -( $EPRX $EXAS $MENS $MTWO $PACS $VIX $WMT Rise!)

by Vista Partners LLC November 20, 2025 3424Views 0Likes

In the end, Thursday looked like a market attempting to renegotiate its relationship with AI, tariffs and the Fed all at once—discovering, not for the first time, that even in an age of algorithms and GLP‑1s, gravity still has a vote. Indexes…

Johnson & Johnson

Your Guide To Staying Informed In The Markets